<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077072</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0337</org_study_id>
    <secondary_id>NCI-2021-09426</secondary_id>
    <secondary_id>2021-0337</secondary_id>
    <nct_id>NCT05077072</nct_id>
  </id_info>
  <brief_title>Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients</brief_title>
  <official_title>Opioid-Sparing Interdisciplinary Interventions Addressing Pain in Head and Neck Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial compares different pain management interventions (standard of care [SOC],&#xD;
      neurofeedback [NFB] training, and compassionate high alert team [CHAT]) in patients diagnosed&#xD;
      with head and neck cancer who are at risk of developing non-medical opioid use (NMOU). The&#xD;
      current standard treatment includes regular clinic visits and supportive care and counseling&#xD;
      (including topics like patient-doctor communication, cancer care goals, financial issues&#xD;
      counseling, and other topics). NFB training is a type of therapy that uses an&#xD;
      electroencephalograph (EEG) and a computer software program to measure brain wave activity.&#xD;
      The goal of NFB is to help teach patients with pain how to change their own brain waves to&#xD;
      lower their feelings of pain and help improve their quality of life. CHAT is a supportive&#xD;
      care intervention that includes symptom and pain management, counseling (about pain,&#xD;
      symptoms, opioid use and safety, stress, and quality of life), and support for patients and&#xD;
      their family members. NFB and CHAT may help to manage pain and lower patient use of opioids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To test the hypothesis that this study will be feasible, as defined by adequate rates of&#xD;
      adherence in the CHAT and NFB groups.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To examine the frequency of NMOU behaviors at the end of 3 months after CHAT, NFB, and&#xD;
      SOC.&#xD;
&#xD;
      II. Examine the pain severity (area under the curve [AUC]), daily opioid use AUC of the&#xD;
      cumulative morphine equivalent daily dose (MEDD), and mood (Hospital Anxiety and Depression&#xD;
      Scale, HADS) for each of the treatment arms (CHAT, NFB, or SOC) in head and neck cancer (HNC)&#xD;
      patients receiving radiation therapy at the end of 3 months.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To examine the cortical and subcortical regions of the brain associated with pain and our&#xD;
      interventions (CHAT, NFB, and SOC) and the extent to which changes in electroencephalogram&#xD;
      (EEG) patterns mediate the effects of the intervention.&#xD;
&#xD;
      OUTLINE: Patients are randomized into 1 of 3 arms.&#xD;
&#xD;
      ARM I: Patients participate in CHAT counseling intervention over 45-60 minutes twice a month&#xD;
      for up to 12 weeks.&#xD;
&#xD;
      ARM II: Patients undergo NFB intervention over 20-30 minutes twice a week for up to 10 weeks.&#xD;
&#xD;
      ARM III: Patients receive 2-3 standard of care sessions per month over 45-60 minutes for up&#xD;
      to 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of non-medical opioid use (NMOU) behaviors</measure>
    <time_frame>through study completion, an average of a year.</time_frame>
    <description>Composite NMOU score is calculated by summing the number of times each behavior suggestive of NMOU is recorded.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Head and Neck Carcinoma</condition>
  <arm_group>
    <arm_group_label>ARM I (CHAT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients participate in CHAT counseling intervention over 45-60 minutes twice a month for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM II (NFB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo NFB intervention over 20-30 minutes twice a week for up to 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM III (SOC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 2-3 standard of care sessions per month over 45-60 minutes for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive SOC</description>
    <arm_group_label>ARM III (SOC)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Counseling</intervention_name>
    <description>Participate in CHAT counseling intervention</description>
    <arm_group_label>ARM I (CHAT)</arm_group_label>
    <other_name>Counseling Intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electroencephalography</intervention_name>
    <description>Undergo EEG</description>
    <arm_group_label>ARM II (NFB)</arm_group_label>
    <other_name>EEG</other_name>
    <other_name>electroencephalogram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Neurofeedback</intervention_name>
    <description>Undergo NFB intervention</description>
    <arm_group_label>ARM II (NFB)</arm_group_label>
    <other_name>EEG biofeedback</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>ARM I (CHAT)</arm_group_label>
    <arm_group_label>ARM II (NFB)</arm_group_label>
    <arm_group_label>ARM III (SOC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of HNC, with patient scheduled to receive radiation therapy, with or without&#xD;
             evidence of active disease&#xD;
&#xD;
          -  Willingness to be seen in the outpatient supportive care center (SCC)&#xD;
&#xD;
          -  History of use of non-medical opioid use (Screener and Opioid Assessment for Patients&#xD;
             with Pain [SOAPP] &gt;= 7+ and/or Cut Down, Annoyed, Guilty, and Eye opener questionnaire&#xD;
             [CAGE] &gt;= 2+)&#xD;
&#xD;
          -  Physician-estimated prognosis of at least 12 months&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Able to complete study assessments&#xD;
&#xD;
          -  Willing to sign written informed consent&#xD;
&#xD;
          -  Both human papillomavirus (HPV) and non-HPV patients will be included&#xD;
&#xD;
          -  Patients currently receiving opioids for at least 1 week&#xD;
&#xD;
          -  Able to read, write and speak English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individual with clinically evident impaired cognition by Memorial Delirium Assessment&#xD;
             Scale (MDAS) score of &gt;= 13&#xD;
&#xD;
          -  Employees of MD Anderson Cancer Center&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Yennu</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sriram Yennu</last_name>
      <phone>713-792-6085</phone>
      <email>syennu@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Sriram Yennu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

